Home/Pipeline/VIAL-INHBE (siRNA)

VIAL-INHBE (siRNA)

Obesity

Phase 1Active

Key Facts

Indication

Obesity

Phase

Phase 1

Status

Active

Company

VIAL Dermatology CRO

About VIAL Dermatology CRO

VIAL is a private, pre-revenue biotech company pioneering a tech-enabled approach to drug discovery and development. Its core strategy integrates computational target discovery, AI-driven molecule design (for antibodies, siRNA, and small molecules), and an automated clinical trial platform to increase speed and scalability. The company's initial pipeline features two Phase 1-ready assets in immunology and metabolic disease, positioning it to address significant unmet needs in large markets like atopic dermatitis, asthma, and obesity.

View full company profile

Therapeutic Areas

Immunology Dermatology Metabolic Disease

Other Obesity Drugs

Drug	Company	Phase	Status
Tirzepatide (Zepbound)	Eli Lilly	Approved	Commercial
APJ Program	BioAge Labs	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Approved	Recently approved in US
Amylin analogue (subcutaneous)	Novo Nordisk	Phase 1	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Phase 2	Active
VK2735 (subcutaneous)	Viking Therapeutics	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Phase 1/2	Active
GSBR-1290	Structure Therapeutics	Phase 2	Active, not recruiting
LTSE-2578	Structure Therapeutics	Preclinical	Lead Optimization
Survodutide (BI 456906)	Zealand Pharma	Phase 3	Active
ZP8396	Zealand Pharma	Preclinical/Phase 1	Active
Pemvidutide (ALT-801)	Altimmune	Phase 2	Active